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Introduction Course	of	the	disease
Hypertrophic cardiomyopathy (HCM) is one of the most common heart diseases that affect people (1:500). Despite
being a dominant autosomal disease, it has different degrees of severity because the phenotype expression depends
on many factors, some of which are still not completely clear. Individuals with the same genotype may present
different phenotypes, from not presenting any symptoms to a sudden death. The disease can be initially silenced and
manifested over time and can affect from young athletes to adults. Because it concerns so many people and it’s often
difficult to diagnose, scientists are interested in finding new techniques to detect the disease more prematurely and
also developmore effective treatments to avoid the most serious symptoms.
HCM is a structural and functional alteration of the myocardium, the muscle responsible for the heart contraction.
Due to mutations in several genes that encode for sarcomere proteins, the left ventricular wall manifests cell disorder,
fibrosis, rigidity, hyperdynamic contraction and diastolic dysfunction, causing its thickening. Because the blood
volume to be pumped is smaller for that reason, not enough oxygenated blood is available throughout the body.
The disease can develop in different ways because of different factors:
• Allelic imbalance: One of the alleles is more expressed than the other and, if it is also mutated, produces
a mosaicism in the tissue that does not maintain its proper functioning.
• Epigenetics: These are all the cellular mechanisms that regulate genes expression (methylation,
acetylation, phosphorylation, etc.). If those modify the promoter regions of the mutated genes, it can be
stimulated the manifestation of hypertrophy.
• Other risk factors: Gender, blood pressure and physical activity.
The	main	perceivable	symptoms	of	MCH	
can	be	identified	with	the	acronym	"SAD"
Syncope	and	Sudden	death	
Angina	
Dyspnea
Signaling	pathways	of	hypertrophy
Against a stress, such as the lack of oxygen, the cell activates a
compensatory response called hypertrophy. This makes the heart
grow and increase its contraction capacity. Once solved the problem,
it stops signaling to activate hypertrophic genes. The problem arises
when the stress does not disappear or there are mutations in some
proteins that causes the signaling pathway to be constantly
stimulated. That’s when the pathology appears in the form of HCM.
Sarcomeric	protein	mutations
Pharmacological	treatments
• Smooth	muscle	cell
• Heart	muscle	cell
Antihypertensives vasodilators
Categories Examples
1. ACE inhibitors Captopril,	Enalapril,	Lisinopril,	
Ramipril.
2. AT1 antagonists Losartan,	Valsartan,	Irbesartan.
3.Mixed β-blockers Labetalol,	Carvedilol.
4. Ca2+channel antagonists • Non	dihydropiridinic
Verapamil,	Diltiazem.
• Dihydropiridinic
Amlodipine,	Nifedipine,
Felodipine,	Nicardipine.
5. KIR channel activators Cromakalim,	Pinacidil,	Diazoxide.
6. Non-selective β-blockers Alprenolol,	Carteolol,	Nadolol,	
Oxprenolol,	Propranolol,	Sotalol.
7. β2 selective β-blockers Butoxamine,	
ICI	118551,	
α-methyl	propanolol.
8. PDE inhibitors Sildenafil,	Vardenafil,	Tadalafil.
Antiarrhythmics
Class Categories Examples
I 9. Na+channel blockers • Ia
Disopyramide,	
Procainamide,	
Quinidine.
• Ib
Lidocaine,	
Phenytoin.
• Ic
Flecainide,	
Propafenone.
II 10. β1 selective β-blockers Atenolol,	Acebutolol,	
Betaxolol,	Esmolol,	
Metoprolol,	Propanolol.
III 11. K+ channel blockers Amiodarone,	Bretylium.
IV 12. Ca2+channel blockers Verapamil,	Diltiazem.
V Na+-K+ pump blockers Digoxin.
Diagnosis
Invasive	treatments
New	inhibitory	molecule	
for	sarcomeric	contraction
Conclusions
Although hypertrophic cardiomyopathy affects many people, there are still no perfect diagnostic techniques or medicines to
prevent or cure the disease. For the future, we should understand better how mutations and signaling pathways lead to the
disease in order to find better treatments. These should be focused on regenerative therapies or molecules specifically targeted
to sarcomeric proteins in order to inhibit hypercontraction.
MYK-461
It has been possible to synthesize a
molecule called MYK-461 (commercial
name: Mavacampten), which binds to
the heavy chain of myosin and inhibits its
ATPase function. By making the release of
the inorganic phosphate slower, it is
possible to reduce the contraction force.
It’s still in phase II, but it’s also giving
good results. Apart from attenuating the
contraction force, cell organization is
recovered, hypertrophy of the ventricular
walls is reversed and the number of
genes affected by HCM is decreased.
Other	treatments	à
1. An automated implantable cardioverter defibrillator
(AICD) is a small device placed under the skin that
measures and controls the heart rate. Facing
bradyarrhythmia it acts as a pacemaker, giving small
electric impulses, and in front a tachycardia it releases a
much more powerful discharge to return to normal rate.
2. Septal myectomy is a surgical
procedure that consists in making a
longitudinal incision in the hypertrophic
septum in order to decrease its thickness.
3. Alcohol septal ablation reduces the
thickness of the septum using alcohol,
which resects the tissue.
1
2
3
Gene therapy with viral vectors and induced pluripotent stem cells (iPSC).
Both still require many years of research and need to be approved by
regulatory agencies before they can be considered therapies to cure a disease.
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* There are certain biomarkers that indicate the onset of HCM such as natriuretic peptides and miRNAs. But they still need to be more studied
in order toknow how to use them correctly as diagnostic tools.
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